Overview
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.
Description
The patients will be treated with 6/8 cycles of orelabrutinib plus R-CHOP regimen（21 days per cycle). The primary objective was the complete response rate (CRR) at end of induction therapy
Eligibility
Inclusion Criteria:
- Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma
- Age 18-70 years
- ECOG performance status 0-2
- Ann Arbor stage II-IV
- 8.Subjects who in line with the testing standard of the clinical trial laboratory
- Life expectancy ≥ 3months
Exclusion Criteria:
- • systemic lymphoma involved CNS.
- Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases.
- uncontrolled infections (including HBV, HCV, HIV/AIDS)
- Subjects who prepared for transplantation
- Pregnancy or active lactation